Do Peptides Build Muscle? Human Evidence and Risks
Peptide marketing often points to higher growth hormone or changes in lean mass. This guide examines what those results tell us about muscle growth—and where the evidence stops.
Key takeaways
- The available human studies do not establish muscle growth or strength gains from CJC-1295 or ipamorelin in healthy lifters.
- An increase in lean mass can include water. In a trial of 96 recreational athletes, injected growth hormone increased lean mass through a rise in extracellular water.[8]
- Tesamorelin has an FDA-approved use for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.[4]
What the muscle-growth studies measured
Editorially updated November 15, 2026. This revision is awaiting medical review. The reviewer in the byline reviewed an earlier version.
Start with what each study measured. A change in hormone levels answers a different question from a change in muscle size or strength. The table below separates those outcomes and identifies who was studied. Findings apply to the compound and formulation tested.
| Compound | Who or what was studied | What the study showed | What remains unproven |
|---|---|---|---|
| CJC-1295 with DAC | Healthy adults in short randomized trials. | GH and IGF-1 rose for several days.[1] | Muscle size, strength and outcomes with products sold as “no DAC” were untested. |
| Ipamorelin | Preclinical experiments in the often-cited selectivity study. | Selective GH release under study conditions.[2] | Muscle growth, strength and long-term safety in healthy lifters. |
| Sermorelin | 19 adults aged 55–71 given a related, norleucine-substituted GHRH analog. | GH and body-composition outcomes were measured after a placebo phase and 16 weeks of the analog.[3] | The tested analog was not sermorelin itself; these findings do not establish a result in healthy lifters. |
| Tesamorelin | Adults with HIV-associated lipodystrophy. | Reduced excess abdominal fat in the population covered by the FDA label.[4] | Muscle or strength gains in healthy lifters. |
| GHRP-2 and GHRP-6 | Small human studies of hormone responses. | Both stimulate GH release. GHRP-2 also increased food intake in a small study of healthy men.[5][6] | Greater muscle growth, strength or training recovery. |
| MK-677 (ibutamoren), an oral non-peptide | 65 healthy adults aged 60–81 in a randomized trial. | At 12 months, fat-free mass rose 1.1 kg with MK-677 and fell 0.5 kg with placebo. Fasting glucose rose and insulin sensitivity decreased.[7] | The trial found no improvement in strength or physical function. |
Lean mass includes more than muscle
Lean mass includes water. In a randomized trial of 96 recreational athletes, the increase in measured lean body mass with injected growth hormone came from extracellular water.[8]
Strength tells another part of the story. A meta-analysis of placebo-controlled GH trials in healthy young adults found increased lean mass without improved muscle strength. Both sources studied injected GH; they cannot tell us what happens with drugs that stimulate GH release.[9]
A DXA scan estimates lean tissue. To interpret a muscle-building claim, look for a direct measure of muscle size, such as MRI or ultrasound, and a strength test that matches the claim.
Does the CJC-1295 and ipamorelin stack build muscle?
The two studies commonly cited for this stack tested different things. Researchers gave CJC-1295 in its long-acting DAC formulation on its own and measured hormone levels. The ipamorelin selectivity study was preclinical.[1][2]
Neither study tested the combination against placebo using muscle size or strength as an outcome. The missing comparison is the stack itself: its results cannot be calculated by putting two separate studies side by side.
Recovery claims: BPC-157 and TB-500
BPC-157 and TB-500 are marketed for recovery, including together as the “Wolverine stack.” A 2026 systematic review of human BPC-157 research found three small studies involving 30 people across different uses. Those studies were too limited to support claims of muscle growth or faster recovery in healthy lifters. Research on full-length thymosin beta-4 also leaves a gap: it cannot tell us the effects of the TB-500 fragment or whether combining it with BPC-157 helps.[10][11]
For a closer look at recovery outcomes, read the peptide recovery evidence guide. The tendon repair guide focuses on claims about injured tendons.
Safety, U.S. approval status and tested sport
Risks depend on the compound, formulation and route. The tesamorelin label warns about glucose intolerance, fluid retention and elevated IGF-1. FDA has flagged potential safety issues for some compounded peptides, including limited safety data for ipamorelin and reports of increased heart rate and systemic vasodilation associated with CJC-1295.[4][12]
U.S. status checked November 15, 2026. None of the compounds in the comparison table is FDA-approved for bodybuilding. HHS issued a conditional enforcement policy for certain uses of specified bulk substances under section 503A, including BPC-157 and TB-500 subject to the policy’s conditions. The policy concerns compounding enforcement. Products compounded under it remain unapproved drugs.[4][13]
Tested sport. WADA prohibits CJC-1295, ipamorelin, sermorelin, tesamorelin, GHRP-2, GHRP-6, ibutamoren and TB-500 under S2, and BPC-157 under S0. These prohibitions apply in and out of competition. Check the current list by substance name with your anti-doping organization.[14]
Training and nutrition
Progressive resistance training is the starting point. A meta-analysis of randomized trials found that protein supplementation can modestly improve gains in muscle size and strength during resistance training. If you are losing muscle or strength unexpectedly, a clinician can help evaluate the cause.[15]
Frequently Asked Questions
How much muscle can I gain, and how long does it take?
Do oral peptides work for muscle growth?
What is the difference between HGH, GH secretagogues and anabolic steroids?
Can women or adults over 50 use peptides to gain muscle?
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Authorship and review information are shown where recorded; an editorial update is not a new medical review.
Related Articles
Molecules in this guide
Browse the molecule library →Compare the research, safety questions and regulatory context for each molecule. Inclusion in this guide does not establish effectiveness or treatment availability.
Looking for care? View Strong Health locations and visit options.
Questions About Changes in Muscle or Strength?
A clinician can help assess changes in strength, review your symptoms and discuss the evidence and risks of treatment options.
References & Citations
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
- Khorram O, et al. Endocrine and metabolic effects of long-term administration of a GHRH analog in age-advanced men and women. J Clin Endocrinol Metab. 1997.
- FDA. EGRIFTA WR (tesamorelin) prescribing information.
- Laferrère B, et al. Growth hormone releasing peptide-2, like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005.
- Growth hormone-releasing peptide-6 requires endogenous hypothalamic growth hormone-releasing hormone for maximal growth hormone stimulation. J Clin Endocrinol Metab. 1998.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008.
- Meinhardt U, et al. The effects of growth hormone on body composition and physical performance in recreational athletes. Ann Intern Med. 2010.
- Impact of GH administration on athletic performance in healthy young adults. A systematic review and meta-analysis. Growth Horm IGF Res. 2017.
- Human evidence for BPC-157 in orthopaedic and regenerative medicine. A systematic review of efficacy and safety. 2026.
- Investigational peptides in orthopaedic practice. Evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. 2026.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.
- HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. October 2026.
- World Anti-Doping Agency. The Prohibited List, sections S0 and S2.
- Morton RW, et al. Protein supplementation and resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018.